Voya Investment Management LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 103.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 317,399 shares of the company's stock after buying an additional 161,230 shares during the period. Voya Investment Management LLC owned 0.15% of Revolution Medicines worth $65,149,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RVMD. Equitable Holdings Inc. bought a new position in shares of Revolution Medicines during the 2nd quarter worth $963,000. State of Wyoming purchased a new stake in Revolution Medicines in the 2nd quarter worth about $1,769,000. Handelsbanken Fonder AB increased its holdings in Revolution Medicines by 243.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company's stock worth $39,755,000 after acquiring an additional 150,500 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Revolution Medicines in the 2nd quarter valued at about $112,566,000. Finally, Assenagon Asset Management S.A. bought a new stake in Revolution Medicines in the 2nd quarter valued at about $37,547,000. Hedge funds and other institutional investors own 94.34% of the company's stock.
Analyst Ratings Changes
Several research firms have commented on RVMD. Sanford C. Bernstein upped their price objective on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a "market perform" rating in a report on Friday, August 21st. UBS Group increased their target price on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a "buy" rating in a research report on Friday, August 28th. Piper Sandler lifted their target price on shares of Revolution Medicines from $210.00 to $222.00 and gave the stock an "overweight" rating in a research note on Thursday, November 5th. Wedbush lifted their target price on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an "outperform" rating in a research note on Thursday, August 27th. Finally, Wolfe Research reissued an "outperform" rating and issued a $220.00 price target on shares of Revolution Medicines in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $262.75.
Get Our Latest Research Report on RVMD
Revolution Medicines Stock Down 1.8%
Shares of NASDAQ RVMD opened at $159.82 on Thursday. The company has a current ratio of 8.36, a quick ratio of 8.34 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $191.75 and a 200-day moving average of $160.40. The firm has a market capitalization of $34.57 billion, a price-to-earnings ratio of -17.54 and a beta of 1.44. Revolution Medicines, Inc. has a 12 month low of $69.50 and a 12 month high of $224.31.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, beating analysts' consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analysts' expectations of $25.58 million. During the same period in the prior year, the business earned ($1.61) earnings per share. Sell-side analysts expect that Revolution Medicines, Inc. will post -7.41 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, insider Stephen Kelsey sold 92,531 shares of the firm's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the sale, the insider owned 291,876 shares in the company, valued at approximately $59,064,027.36. This trade represents a 24.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark A. Goldsmith sold 80,000 shares of Revolution Medicines stock in a transaction on Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the sale, the insider directly owned 267,330 shares of the company's stock, valued at $55,925,436. This represents a 23.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 353,901 shares of company stock worth $70,706,418. 7.60% of the stock is owned by corporate insiders.
About Revolution Medicines
(
Free Report)
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers. The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Revolution Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.
While Revolution Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.